Cat. No. | Product name | CAS No. |
DC2018 |
LY335979 (Zosuquidar 3HCl)
Featured
LY335979 (Zosuquidar) is a potent modulator of P-glycoprotein-mediated multidrug resistance with Ki of 60 nM. |
167465-36-3 |
DC10560 |
MAK683
Featured
MAK683 is a novel PRC2/EED inhibitor. |
1951408-58-4 |
DC8031 |
Marimastat
Marimastat is a broad spectrum MMP inhibitor and selective TACE inhibitor |
154039-60-8 |
DC7460 |
Masitinib
Featured
Masitinib is a broad coronavirus 3CL inhibitor that effectively blocks replication of SARS-CoV-2. Science 20 Jul 2021: eabg5827 DOI: 10.1126/science.abg5827 |
790299-79-5 |
DC5069 |
Enzalutamide (MDV3100)
Featured
MDV3100 is an androgen-receptor (AR) antagonist with IC50 of 36 nM. |
915087-33-1 |
DC9050 |
Melphalan
Featured
Melphalan(Sarcolysin; L-PAM) is a chemotherapy drug belonging to the class of nitrogen mustard alkylating agents; attaches the alkyl group to the guanine base of DNA. |
148-82-3 |
DC4182 |
Temozolomide
Featured
Methazolastone (Temozolomide, Temodar, Temodal) is a DNA damage inducer. |
85622-93-1 |
DCAPI1146 |
Methoxsalen (Oxsoralen)
Methoxsalen (Oxsoralen) |
298-81-7 |
DC7196 |
MGCD0103 (Mocetinostat)
Featured
MGCD0103 (Mocetinostat) is a potent HDAC inhibitor with IC50 of 0.15, 0.29 and 1.66 μM for HDAC 1, HDAC 2 and HDAC 3, respectively. |
726169-73-9 |
DC8545 |
MI-503
Featured
MI-503 is a highly potent and orally bioavailable small molecule inhibitor of the menin-MLL interaction. |
1857417-13-0 |
DC8414 |
MI-77301 (SAR405838)
Featured
MI-77301 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1. |
1303607-60-4 |
DC9836 |
Mivebresib(ABBV-075)
Featured
Mivebresib is a novel BET family inhibitor, disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo. |
1445993-26-9 |
DC1070 |
MK-1775(AZD-1775,Adavosertib)
Featured
MK-1775 is a potent and selective Wee1 inhibitor with IC50 of 5.2 nM. |
955365-80-7 |
DC7465 |
MK-2206 2HCl
Featured
MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2. |
1032350-13-2 |
DC8479 |
MK-2461
MK-2461 is a potent, multi-targeted inhibitor for c-Met(WT/mutants) with IC50 of 0.4-2.5 nM, less potent to Ron, Flt1; 8- to 30-fold greater selectivity of c-Met targets versus FGFR1, FGFR2, FGFR3, PDGFRβ, KDR, Flt3, Flt4, TrkA, and TrkB. |
917879-39-1 |
DC9707 |
MK-4101
Featured
MK-4101 is a potent SMO Inhibitor of the Hedgehog Pathway, highly active against Medulloblastoma and Basal Cell Carcinoma. |
935273-79-3 |
DC4179 |
Niraparib(MK4827) free base
Featured
MK-4827 is an inhibitor of poly (ADP-ribose) polymerase (PARP) with potential antineoplastic activity. |
1038915-60-4 |
DC9862 |
Niraparib(MK4827) hydrochloride
Featured
MK-4827 is an inhibitor of poly (ADP-ribose) polymerase (PARP) with potential antineoplastic activity. |
1038915-64-8 |
DC9576 |
Niraparib tosylate
Featured
MK-4827(Niraparib) tosylate is a selective inhibitor of PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM; with great activity in cancer cells with mutant BRCA-1 and BRCA-2; >330-fold selective against PARP3, V-PARP and Tank1. |
1038915-73-9 |
DC7466 |
MK-5108
MK-5108 (VX-689) is a highly selective Aurora A inhibitor with IC50 of 0.064 nM; 220- and 190-fold more selective for Aurora A than Aurora B/C. |
1010085-13-8 |
DC9682 |
ML-264
Featured
ML264 is a novel small molecule inhibitor of Krüppel-like factor 5 (KLF5). |
1550008-55-3 |
DC10282 |
ML385
Featured
ML385 is a novel and specific NRF2 inhibitor. |
846557-71-9 |